Investor Relations
NASDAQ: ERNA
Pricing delayed by 20 minutes
Last updated
Corporate overview
“Eterna” Therapeutics is developing transformative new medicines to treat various forms of cancer and other diseases with high unmet medical needs.
Eterna’s product pipeline is based on extensively patented foundational mRNA cell engineering technology and offers multiple clinical applications with future sub-licensing and partnering opportunities. Eterna has recruited an experienced leadership team with deep expertise in mRNA cell engineering and cell and gene therapy product development.
Latest presentation
December 09, 2024
Eterna Therapeutics Fact Sheet
Download PDF
Latest events
Contact Us
investors@eternatx.com
Shareholder services/Website:
Phone:

1 (800) 736-3001 (U.S.)

1 (781) 575-3100 (non-U.S.)

Email:
investors@eternatx.com
Regular mail:

Computershare

P.O. Box 43006


Providence RI, 02940-3006

Courier Delivery:

Computershare
150 Royall St.,

Suite 101
Canton,

MA 02021

investor email alerts
Unsubscrbe